Institute 7 - Advanced Tissue Biofabrication Manufacturing Innovation Institute (ATB-MII)
Abstract
This institute is intended to advance state-of-the-art human tissue manufacturing innovations in cell and biomaterial processing, bioprinting, automation and non-destructive testing technologies. The motivation is to increase U.S. competitiveness in advanced tissue biofabrication manufacturing by encouraging insertion of disruptive technologies into multiple biotechnology sectors, streamlining integrated testing technologies and ultimately reducing the barrier to entry for new inventors. The goal is to establish a collaboration that will mature tissue-related technology across a range of manufacturing readiness levels (MRL) 4-7, enabling post-delivery assurance of tissue identity, viability, function, and efficacy. This Institute will bring together the diverse and currently fragmented collection of industry practices and institutional knowledge across many disciplines (cell biology, bioengineering, materials science, analytical chemistry, robotics, and quality assurance). Scaling up to commercial level production of tissues will require manufacturing and process automation suitable for living cells, as well as testing and preservation methods appropriate for tissue-based products with limited shelf-life and a narrow window of efficacy. Technical focus at a minimum will be comprised of four thrust areas: 1) Cell & Material Selection & Sourcing; 2) Biofabrication Platforms; 3) Process Design and Automation; 4) Tissue Finishing and Testing Technologies This institute was established in late 2016. Technology Investment Agreement funds are programmed in this budget from FY 2016 through FY 2022.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2018
- Source ID
- 3d5efa0154e6931621799f6cdc49449b